Advocacy intelligence hub — real-time data for patient organizations
CLINDAMYCIN PHOSPHATE: FDA approved
Hospices Civils de Lyon — NA
Kyowa Kirin Co., Ltd. — PHASE1
Wuerzburg University Hospital
Massachusetts General Hospital — EARLY_PHASE1
Ultragenyx Pharmaceutical Inc
Kyowa Kirin Co., Ltd.
Kyowa Kirin Pharmaceutical Development Ltd
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Crysvita
(burosumab-twza)Orphan drugstandardKyowa Kirin, Inc.
12.1 Mechanism of Action X-linked hypophosphatemia is caused by excess fibroblast growth factor 23 (FGF23) which suppresses renal tubular phosphate re...
Amy Zhang, PhD
Kyowa Hakko Kirin Pharma, Inc.
Thomas O. Carpenter, MD
Yale University
Lothar Seefried, MD
University Hospital Wuerzburg
Lars Rejnmark
Dept. of Endocrinology and Internal Medicine, The Osteoporosis Clinic
Eva Liu, MD
Massachusetts General Hospital and Brigham and Women's Hospital
Lea Bentur, Prof.
Rambam MC